Stemline Therapeutics elects Kevin Buchi to board
This article was originally published in Scrip
Executive Summary
Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells and tumour bulk, has appointed Kevin Buchi to its board of directors. Mr Buchi, who was previously CEO of Cephalon before its acquisition by Teva Pharmaceutical Industries, now serves as corporate vice-president of global branded products for Teva.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.